ID   ABCC9_HUMAN             Reviewed;        1549 AA.
AC   O60706; O60707;
DT   26-SEP-2001, integrated into UniProtKB/Swiss-Prot.
DT   25-NOV-2008, sequence version 2.
DT   10-MAY-2017, entry version 162.
DE   RecName: Full=ATP-binding cassette sub-family C member 9;
DE   AltName: Full=Sulfonylurea receptor 2;
GN   Name=ABCC9; Synonyms=SUR2;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] (ISOFORMS SUR2A AND SUR2B), AND
RP   REVIEW.
RX   PubMed=9457174;
RA   Aguilar-Bryan L., Clement J.P. IV, Gonzalez G., Kunjilwar K.,
RA   Babenko A., Bryan J.;
RT   "Toward understanding the assembly and structure of KATP channels.";
RL   Physiol. Rev. 78:227-245(1998).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=16541075; DOI=10.1038/nature04569;
RA   Scherer S.E., Muzny D.M., Buhay C.J., Chen R., Cree A., Ding Y.,
RA   Dugan-Rocha S., Gill R., Gunaratne P., Harris R.A., Hawes A.C.,
RA   Hernandez J., Hodgson A.V., Hume J., Jackson A., Khan Z.M.,
RA   Kovar-Smith C., Lewis L.R., Lozado R.J., Metzker M.L.,
RA   Milosavljevic A., Miner G.R., Montgomery K.T., Morgan M.B.,
RA   Nazareth L.V., Scott G., Sodergren E., Song X.-Z., Steffen D.,
RA   Lovering R.C., Wheeler D.A., Worley K.C., Yuan Y., Zhang Z.,
RA   Adams C.Q., Ansari-Lari M.A., Ayele M., Brown M.J., Chen G., Chen Z.,
RA   Clerc-Blankenburg K.P., Davis C., Delgado O., Dinh H.H., Draper H.,
RA   Gonzalez-Garay M.L., Havlak P., Jackson L.R., Jacob L.S., Kelly S.H.,
RA   Li L., Li Z., Liu J., Liu W., Lu J., Maheshwari M., Nguyen B.-V.,
RA   Okwuonu G.O., Pasternak S., Perez L.M., Plopper F.J.H., Santibanez J.,
RA   Shen H., Tabor P.E., Verduzco D., Waldron L., Wang Q., Williams G.A.,
RA   Zhang J., Zhou J., Allen C.C., Amin A.G., Anyalebechi V., Bailey M.,
RA   Barbaria J.A., Bimage K.E., Bryant N.P., Burch P.E., Burkett C.E.,
RA   Burrell K.L., Calderon E., Cardenas V., Carter K., Casias K.,
RA   Cavazos I., Cavazos S.R., Ceasar H., Chacko J., Chan S.N., Chavez D.,
RA   Christopoulos C., Chu J., Cockrell R., Cox C.D., Dang M.,
RA   Dathorne S.R., David R., Davis C.M., Davy-Carroll L., Deshazo D.R.,
RA   Donlin J.E., D'Souza L., Eaves K.A., Egan A., Emery-Cohen A.J.,
RA   Escotto M., Flagg N., Forbes L.D., Gabisi A.M., Garza M., Hamilton C.,
RA   Henderson N., Hernandez O., Hines S., Hogues M.E., Huang M.,
RA   Idlebird D.G., Johnson R., Jolivet A., Jones S., Kagan R., King L.M.,
RA   Leal B., Lebow H., Lee S., LeVan J.M., Lewis L.C., London P.,
RA   Lorensuhewa L.M., Loulseged H., Lovett D.A., Lucier A., Lucier R.L.,
RA   Ma J., Madu R.C., Mapua P., Martindale A.D., Martinez E., Massey E.,
RA   Mawhiney S., Meador M.G., Mendez S., Mercado C., Mercado I.C.,
RA   Merritt C.E., Miner Z.L., Minja E., Mitchell T., Mohabbat F.,
RA   Mohabbat K., Montgomery B., Moore N., Morris S., Munidasa M.,
RA   Ngo R.N., Nguyen N.B., Nickerson E., Nwaokelemeh O.O., Nwokenkwo S.,
RA   Obregon M., Oguh M., Oragunye N., Oviedo R.J., Parish B.J.,
RA   Parker D.N., Parrish J., Parks K.L., Paul H.A., Payton B.A., Perez A.,
RA   Perrin W., Pickens A., Primus E.L., Pu L.-L., Puazo M., Quiles M.M.,
RA   Quiroz J.B., Rabata D., Reeves K., Ruiz S.J., Shao H., Sisson I.,
RA   Sonaike T., Sorelle R.P., Sutton A.E., Svatek A.F., Svetz L.A.,
RA   Tamerisa K.S., Taylor T.R., Teague B., Thomas N., Thorn R.D.,
RA   Trejos Z.Y., Trevino B.K., Ukegbu O.N., Urban J.B., Vasquez L.I.,
RA   Vera V.A., Villasana D.M., Wang L., Ward-Moore S., Warren J.T.,
RA   Wei X., White F., Williamson A.L., Wleczyk R., Wooden H.S.,
RA   Wooden S.H., Yen J., Yoon L., Yoon V., Zorrilla S.E., Nelson D.,
RA   Kucherlapati R., Weinstock G., Gibbs R.A.;
RT   "The finished DNA sequence of human chromosome 12.";
RL   Nature 440:346-351(2006).
RN   [3]
RP   FUNCTION, AND SUBUNIT.
RX   PubMed=9831708; DOI=10.1161/01.RES.83.11.1132;
RA   Babenko A.P., Gonzalez G., Aguilar-Bryan L., Bryan J.;
RT   "Reconstituted human cardiac KATP channels: functional identity with
RT   the native channels from the sarcolemma of human ventricular cells.";
RL   Circ. Res. 83:1132-1143(1998).
RN   [4]
RP   POSSIBLE FUNCTION IN REGULATION OF SLEEP DURATION.
RX   PubMed=22105623; DOI=10.1038/mp.2011.142;
RA   Allebrandt K.V., Amin N., Muller-Myhsok B., Esko T., Teder-Laving M.,
RA   Azevedo R.V., Hayward C., van Mill J., Vogelzangs N., Green E.W.,
RA   Melville S.A., Lichtner P., Wichmann H.E., Oostra B.A., Janssens A.C.,
RA   Campbell H., Wilson J.F., Hicks A.A., Pramstaller P.P., Dogas Z.,
RA   Rudan I., Merrow M., Penninx B., Kyriacou C.P., Metspalu A.,
RA   van Duijn C.M., Meitinger T., Roenneberg T.;
RT   "A K(ATP) channel gene effect on sleep duration: from genome-wide
RT   association studies to function in Drosophila.";
RL   Mol. Psychiatry 18:122-132(2013).
RN   [5]
RP   VARIANT CMD1O THR-1513.
RX   PubMed=15034580; DOI=10.1038/ng1329;
RA   Bienengraeber M., Olson T.M., Selivanov V.A., Kathmann E.C.,
RA   O'Cochlain F., Gao F., Karger A.B., Ballew J.D., Hodgson D.M.,
RA   Zingman L.V., Pang Y.-P., Alekseev A.E., Terzic A.;
RT   "ABCC9 mutations identified in human dilated cardiomyopathy disrupt
RT   catalytic KATP channel gating.";
RL   Nat. Genet. 36:382-387(2004).
RN   [6]
RP   VARIANT ATFB12 ILE-1547, AND CHARACTERIZATION OF VARIANT ATFB12
RP   ILE-1547.
RX   PubMed=17245405; DOI=10.1038/ncpcardio0792;
RA   Olson T.M., Alekseev A.E., Moreau C., Liu X.K., Zingman L.V., Miki T.,
RA   Seino S., Asirvatham S.J., Jahangir A., Terzic A.;
RT   "KATP channel mutation confers risk for vein of Marshall adrenergic
RT   atrial fibrillation.";
RL   Nat. Clin. Pract. Cardiovasc. Med. 4:110-116(2007).
RN   [7]
RP   VARIANTS HTOCD VAL-478; TYR-1043; GLN-1154 AND TRP-1154.
RX   PubMed=22608503; DOI=10.1016/j.ajhg.2012.04.014;
RA   van Bon B.W., Gilissen C., Grange D.K., Hennekam R.C., Kayserili H.,
RA   Engels H., Reutter H., Ostergaard J.R., Morava E., Tsiakas K.,
RA   Isidor B., Le Merrer M., Eser M., Wieskamp N., de Vries P.,
RA   Steehouwer M., Veltman J.A., Robertson S.P., Brunner H.G.,
RA   de Vries B.B., Hoischen A.;
RT   "Cantu syndrome is caused by mutations in ABCC9.";
RL   Am. J. Hum. Genet. 90:1094-1101(2012).
RN   [8]
RP   VARIANTS HTOCD TYR-60; GLU-207; CYS-380; LEU-432; PRO-1020; SER-1039;
RP   TYR-1054; HIS-1116; CYS-1116; GLN-1154 AND TRP-1154, AND
RP   CHARACTERIZATION OF VARIANTS HTOCD LEU-432; HIS-1116 AND GLN-1154.
RX   PubMed=22610116; DOI=10.1038/ng.2324;
RA   Harakalova M., van Harssel J.J., Terhal P.A., van Lieshout S.,
RA   Duran K., Renkens I., Amor D.J., Wilson L.C., Kirk E.P., Turner C.L.,
RA   Shears D., Garcia-Minaur S., Lees M.M., Ross A., Venselaar H.,
RA   Vriend G., Takanari H., Rook M.B., van der Heyden M.A.,
RA   Asselbergs F.W., Breur H.M., Swinkels M.E., Scurr I.J., Smithson S.F.,
RA   Knoers N.V., van der Smagt J.J., Nijman I.J., Kloosterman W.P.,
RA   van Haelst M.M., van Haaften G., Cuppen E.;
RT   "Dominant missense mutations in ABCC9 cause Cantu syndrome.";
RL   Nat. Genet. 44:793-796(2012).
RN   [9]
RP   VARIANTS HTOCD LEU-432; VAL-478 AND TYR-1043, AND CHARACTERIZATION OF
RP   VARIANTS HTOCD LEU-432; VAL-478 AND TYR-1043.
RX   PubMed=26621776; DOI=10.1085/jgp.201511495;
RA   Cooper P.E., Sala-Rabanal M., Lee S.J., Nichols C.G.;
RT   "Differential mechanisms of Cantu syndrome-associated gain of function
RT   mutations in the ABCC9 (SUR2) subunit of the KATP channel.";
RL   J. Gen. Physiol. 146:527-540(2015).
CC   -!- FUNCTION: Subunit of ATP-sensitive potassium channels (KATP). Can
CC       form cardiac and smooth muscle-type KATP channels with KCNJ11.
CC       KCNJ11 forms the channel pore while ABCC9 is required for
CC       activation and regulation. {ECO:0000269|PubMed:9831708}.
CC   -!- SUBUNIT: Interacts with KCNJ11. {ECO:0000269|PubMed:9831708}.
CC   -!- SUBCELLULAR LOCATION: Membrane {ECO:0000255|PROSITE-
CC       ProRule:PRU00441}; Multi-pass membrane protein
CC       {ECO:0000255|PROSITE-ProRule:PRU00441}.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=2;
CC       Name=SUR2A;
CC         IsoId=O60706-1; Sequence=Displayed;
CC       Name=SUR2B;
CC         IsoId=O60706-2; Sequence=VSP_000058;
CC   -!- DISEASE: Cardiomyopathy, dilated 1O (CMD1O) [MIM:608569]: A
CC       disorder characterized by ventricular dilation and impaired
CC       systolic function, resulting in congestive heart failure and
CC       arrhythmia. Patients are at risk of premature death.
CC       {ECO:0000269|PubMed:15034580}. Note=The disease is caused by
CC       mutations affecting the gene represented in this entry.
CC   -!- DISEASE: Atrial fibrillation, familial, 12 (ATFB12) [MIM:614050]:
CC       A familial form of atrial fibrillation, a common sustained cardiac
CC       rhythm disturbance. Atrial fibrillation is characterized by
CC       disorganized atrial electrical activity and ineffective atrial
CC       contraction promoting blood stasis in the atria and reduces
CC       ventricular filling. It can result in palpitations, syncope,
CC       thromboembolic stroke, and congestive heart failure.
CC       {ECO:0000269|PubMed:17245405}. Note=The disease is caused by
CC       mutations affecting the gene represented in this entry.
CC   -!- DISEASE: Hypertrichotic osteochondrodysplasia (HTOCD)
CC       [MIM:239850]: A rare disorder characterized by congenital
CC       hypertrichosis, neonatal macrosomia, a distinct
CC       osteochondrodysplasia, and cardiomegaly. The hypertrichosis leads
CC       to thick scalp hair, which extends onto the forehead, and a
CC       general increase in body hair. In addition, macrocephaly and
CC       coarse facial features, including a broad nasal bridge, epicanthal
CC       folds, a wide mouth, and full lips, can be suggestive of a storage
CC       disorder. About half of affected individuals are macrosomic and
CC       edematous at birth, whereas in childhood they usually have a
CC       muscular appearance with little subcutaneous fat. Thickened
CC       calvarium, narrow thorax, wide ribs, flattened or ovoid vertebral
CC       bodies, coxa valga, osteopenia, enlarged medullary canals, and
CC       metaphyseal widening of long bones have been reported. Cardiac
CC       manifestations such as patent ductus arteriosus, ventricular
CC       hypertrophy, pulmonary hypertension, and pericardial effusions are
CC       present in approximately 80% of cases. Motor development is
CC       usually delayed due to hypotonia. Most patients have a mild speech
CC       delay, and a small percentage have learning difficulties or
CC       intellectual disability. {ECO:0000269|PubMed:22608503,
CC       ECO:0000269|PubMed:22610116, ECO:0000269|PubMed:26621776}.
CC       Note=The disease is caused by mutations affecting the gene
CC       represented in this entry.
CC   -!- MISCELLANEOUS: May contribute to the regulation of sleep duration.
CC       An intronic variant of this gene may account for about 5% of the
CC       variation of sleep duration between individuals (PubMed:22105623).
CC       Sleep duration is influenced both by environmental and genetic
CC       factors, with an estimated heritability of about 40%. Numerous
CC       genes are expected to contribute to the regulation of sleep
CC       duration. {ECO:0000305|PubMed:22105623}.
CC   -!- SIMILARITY: Belongs to the ABC transporter superfamily. ABCC
CC       family. Conjugate transporter (TC 3.A.1.208) subfamily.
CC       {ECO:0000305}.
CC   -!- WEB RESOURCE: Name=Protein Spotlight; Note=On The Other Side -
CC       Issue 139 of June 2012;
CC       URL="http://web.expasy.org/spotlight/back_issues/139";
CC   -!- WEB RESOURCE: Name=ABCMdb; Note=Database for mutations in ABC
CC       proteins;
CC       URL="http://abcmutations.hegelab.org/proteinDetails?uniprot_id=O60706";
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; AF061323; AAC16057.1; -; Genomic_DNA.
DR   EMBL; AF061289; AAC16057.1; JOINED; Genomic_DNA.
DR   EMBL; AF061290; AAC16057.1; JOINED; Genomic_DNA.
DR   EMBL; AF061291; AAC16057.1; JOINED; Genomic_DNA.
DR   EMBL; AF061292; AAC16057.1; JOINED; Genomic_DNA.
DR   EMBL; AF061293; AAC16057.1; JOINED; Genomic_DNA.
DR   EMBL; AF061294; AAC16057.1; JOINED; Genomic_DNA.
DR   EMBL; AF061295; AAC16057.1; JOINED; Genomic_DNA.
DR   EMBL; AF061296; AAC16057.1; JOINED; Genomic_DNA.
DR   EMBL; AF061297; AAC16057.1; JOINED; Genomic_DNA.
DR   EMBL; AF061298; AAC16057.1; JOINED; Genomic_DNA.
DR   EMBL; AF061299; AAC16057.1; JOINED; Genomic_DNA.
DR   EMBL; AF061300; AAC16057.1; JOINED; Genomic_DNA.
DR   EMBL; AF061301; AAC16057.1; JOINED; Genomic_DNA.
DR   EMBL; AF061302; AAC16057.1; JOINED; Genomic_DNA.
DR   EMBL; AF061303; AAC16057.1; JOINED; Genomic_DNA.
DR   EMBL; AF061304; AAC16057.1; JOINED; Genomic_DNA.
DR   EMBL; AF061305; AAC16057.1; JOINED; Genomic_DNA.
DR   EMBL; AF061306; AAC16057.1; JOINED; Genomic_DNA.
DR   EMBL; AF061307; AAC16057.1; JOINED; Genomic_DNA.
DR   EMBL; AF061308; AAC16057.1; JOINED; Genomic_DNA.
DR   EMBL; AF061309; AAC16057.1; JOINED; Genomic_DNA.
DR   EMBL; AF061310; AAC16057.1; JOINED; Genomic_DNA.
DR   EMBL; AF061311; AAC16057.1; JOINED; Genomic_DNA.
DR   EMBL; AF061312; AAC16057.1; JOINED; Genomic_DNA.
DR   EMBL; AF061313; AAC16057.1; JOINED; Genomic_DNA.
DR   EMBL; AF061314; AAC16057.1; JOINED; Genomic_DNA.
DR   EMBL; AF061315; AAC16057.1; JOINED; Genomic_DNA.
DR   EMBL; AF061316; AAC16057.1; JOINED; Genomic_DNA.
DR   EMBL; AF061317; AAC16057.1; JOINED; Genomic_DNA.
DR   EMBL; AF061318; AAC16057.1; JOINED; Genomic_DNA.
DR   EMBL; AF061319; AAC16057.1; JOINED; Genomic_DNA.
DR   EMBL; AF061320; AAC16057.1; JOINED; Genomic_DNA.
DR   EMBL; AF061321; AAC16057.1; JOINED; Genomic_DNA.
DR   EMBL; AF061322; AAC16057.1; JOINED; Genomic_DNA.
DR   EMBL; AF061324; AAC16058.1; -; Genomic_DNA.
DR   EMBL; AF061289; AAC16058.1; JOINED; Genomic_DNA.
DR   EMBL; AF061290; AAC16058.1; JOINED; Genomic_DNA.
DR   EMBL; AF061291; AAC16058.1; JOINED; Genomic_DNA.
DR   EMBL; AF061292; AAC16058.1; JOINED; Genomic_DNA.
DR   EMBL; AF061293; AAC16058.1; JOINED; Genomic_DNA.
DR   EMBL; AF061294; AAC16058.1; JOINED; Genomic_DNA.
DR   EMBL; AF061295; AAC16058.1; JOINED; Genomic_DNA.
DR   EMBL; AF061296; AAC16058.1; JOINED; Genomic_DNA.
DR   EMBL; AF061297; AAC16058.1; JOINED; Genomic_DNA.
DR   EMBL; AF061298; AAC16058.1; JOINED; Genomic_DNA.
DR   EMBL; AF061299; AAC16058.1; JOINED; Genomic_DNA.
DR   EMBL; AF061300; AAC16058.1; JOINED; Genomic_DNA.
DR   EMBL; AF061301; AAC16058.1; JOINED; Genomic_DNA.
DR   EMBL; AF061302; AAC16058.1; JOINED; Genomic_DNA.
DR   EMBL; AF061303; AAC16058.1; JOINED; Genomic_DNA.
DR   EMBL; AF061304; AAC16058.1; JOINED; Genomic_DNA.
DR   EMBL; AF061305; AAC16058.1; JOINED; Genomic_DNA.
DR   EMBL; AF061306; AAC16058.1; JOINED; Genomic_DNA.
DR   EMBL; AF061307; AAC16058.1; JOINED; Genomic_DNA.
DR   EMBL; AF061308; AAC16058.1; JOINED; Genomic_DNA.
DR   EMBL; AF061309; AAC16058.1; JOINED; Genomic_DNA.
DR   EMBL; AF061310; AAC16058.1; JOINED; Genomic_DNA.
DR   EMBL; AF061311; AAC16058.1; JOINED; Genomic_DNA.
DR   EMBL; AF061312; AAC16058.1; JOINED; Genomic_DNA.
DR   EMBL; AF061313; AAC16058.1; JOINED; Genomic_DNA.
DR   EMBL; AF061314; AAC16058.1; JOINED; Genomic_DNA.
DR   EMBL; AF061315; AAC16058.1; JOINED; Genomic_DNA.
DR   EMBL; AF061316; AAC16058.1; JOINED; Genomic_DNA.
DR   EMBL; AF061317; AAC16058.1; JOINED; Genomic_DNA.
DR   EMBL; AF061318; AAC16058.1; JOINED; Genomic_DNA.
DR   EMBL; AF061319; AAC16058.1; JOINED; Genomic_DNA.
DR   EMBL; AF061320; AAC16058.1; JOINED; Genomic_DNA.
DR   EMBL; AF061321; AAC16058.1; JOINED; Genomic_DNA.
DR   EMBL; AF061322; AAC16058.1; JOINED; Genomic_DNA.
DR   EMBL; AC008250; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; AC084806; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   CCDS; CCDS8693.1; -. [O60706-2]
DR   CCDS; CCDS8694.1; -. [O60706-1]
DR   RefSeq; NP_005682.2; NM_005691.3. [O60706-1]
DR   RefSeq; NP_064693.2; NM_020297.3. [O60706-2]
DR   RefSeq; XP_005253341.1; XM_005253284.3. [O60706-2]
DR   RefSeq; XP_005253343.1; XM_005253286.3. [O60706-2]
DR   RefSeq; XP_005253344.1; XM_005253287.4. [O60706-1]
DR   RefSeq; XP_005253345.1; XM_005253288.3. [O60706-2]
DR   RefSeq; XP_011518847.1; XM_011520545.2. [O60706-2]
DR   UniGene; Hs.732701; -.
DR   ProteinModelPortal; O60706; -.
DR   SMR; O60706; -.
DR   BioGrid; 115371; 3.
DR   IntAct; O60706; 1.
DR   STRING; 9606.ENSP00000261200; -.
DR   BindingDB; O60706; -.
DR   ChEMBL; CHEMBL1971; -.
DR   DrugBank; DB00171; Adenosine triphosphate.
DR   DrugBank; DB01016; Glyburide.
DR   GuidetoPHARMACOLOGY; 2746; -.
DR   TCDB; 3.A.1.208.23; the atp-binding cassette (abc) superfamily.
DR   iPTMnet; O60706; -.
DR   PhosphoSitePlus; O60706; -.
DR   BioMuta; ABCC9; -.
DR   PaxDb; O60706; -.
DR   PeptideAtlas; O60706; -.
DR   PRIDE; O60706; -.
DR   Ensembl; ENST00000261200; ENSP00000261200; ENSG00000069431. [O60706-2]
DR   Ensembl; ENST00000261201; ENSP00000261201; ENSG00000069431. [O60706-1]
DR   GeneID; 10060; -.
DR   KEGG; hsa:10060; -.
DR   UCSC; uc001rfh.4; human. [O60706-1]
DR   CTD; 10060; -.
DR   DisGeNET; 10060; -.
DR   GeneCards; ABCC9; -.
DR   GeneReviews; ABCC9; -.
DR   HGNC; HGNC:60; ABCC9.
DR   HPA; HPA007279; -.
DR   MalaCards; ABCC9; -.
DR   MIM; 239850; phenotype.
DR   MIM; 601439; gene.
DR   MIM; 608569; phenotype.
DR   MIM; 614050; phenotype.
DR   neXtProt; NX_O60706; -.
DR   OpenTargets; ENSG00000069431; -.
DR   Orphanet; 965; Acromegaloid facial appearance syndrome.
DR   Orphanet; 334; Familial atrial fibrillation.
DR   Orphanet; 154; Familial isolated dilated cardiomyopathy.
DR   Orphanet; 966; Hypertrichosis-acromegaloid facial appearance syndrome.
DR   Orphanet; 1517; Hypertrichotic osteochondrodysplasia, Cantu type.
DR   PharmGKB; PA396; -.
DR   eggNOG; KOG0054; Eukaryota.
DR   eggNOG; COG1132; LUCA.
DR   GeneTree; ENSGT00870000136472; -.
DR   HOVERGEN; HBG101342; -.
DR   InParanoid; O60706; -.
DR   KO; K05033; -.
DR   OMA; HAYASGN; -.
DR   OrthoDB; EOG091G00IN; -.
DR   PhylomeDB; O60706; -.
DR   TreeFam; TF105201; -.
DR   Reactome; R-HSA-1296025; ATP sensitive Potassium channels.
DR   Reactome; R-HSA-382556; ABC-family proteins mediated transport.
DR   Reactome; R-HSA-5578775; Ion homeostasis.
DR   GeneWiki; ABCC9; -.
DR   GenomeRNAi; 10060; -.
DR   PRO; PR:O60706; -.
DR   Proteomes; UP000005640; Chromosome 12.
DR   Bgee; ENSG00000069431; -.
DR   CleanEx; HS_ABCC9; -.
DR   ExpressionAtlas; O60706; baseline and differential.
DR   Genevisible; O60706; HS.
DR   GO; GO:0008282; C:ATP-sensitive potassium channel complex; ISS:BHF-UCL.
DR   GO; GO:0005886; C:plasma membrane; TAS:Reactome.
DR   GO; GO:0042383; C:sarcolemma; IBA:GO_Central.
DR   GO; GO:0030017; C:sarcomere; IEA:Ensembl.
DR   GO; GO:0008076; C:voltage-gated potassium channel complex; IDA:BHF-UCL.
DR   GO; GO:0005524; F:ATP binding; IEA:UniProtKB-KW.
DR   GO; GO:0042626; F:ATPase activity, coupled to transmembrane movement of substances; IBA:GO_Central.
DR   GO; GO:0043225; F:ATPase-coupled anion transmembrane transporter activity; TAS:Reactome.
DR   GO; GO:0044325; F:ion channel binding; IPI:BHF-UCL.
DR   GO; GO:0005267; F:potassium channel activity; IEA:Ensembl.
DR   GO; GO:0015459; F:potassium channel regulator activity; ISS:BHF-UCL.
DR   GO; GO:0008281; F:sulfonylurea receptor activity; ISS:BHF-UCL.
DR   GO; GO:0005215; F:transporter activity; TAS:ProtInc.
DR   GO; GO:0051607; P:defense response to virus; IMP:MGI.
DR   GO; GO:0010107; P:potassium ion import; ISS:BHF-UCL.
DR   GO; GO:0006813; P:potassium ion transport; TAS:ProtInc.
DR   GO; GO:1903779; P:regulation of cardiac conduction; TAS:Reactome.
DR   GO; GO:0042493; P:response to drug; IBA:GO_Central.
DR   GO; GO:0055085; P:transmembrane transport; IBA:GO_Central.
DR   InterPro; IPR003593; AAA+_ATPase.
DR   InterPro; IPR011527; ABC1_TM_dom.
DR   InterPro; IPR003439; ABC_transporter-like.
DR   InterPro; IPR017871; ABC_transporter_CS.
DR   InterPro; IPR001475; ABCC9.
DR   InterPro; IPR027417; P-loop_NTPase.
DR   InterPro; IPR000388; Sulphorea_rcpt.
DR   PANTHER; PTHR24223:SF289; PTHR24223:SF289; 1.
DR   Pfam; PF00664; ABC_membrane; 2.
DR   Pfam; PF00005; ABC_tran; 2.
DR   PRINTS; PR01094; SULFNYLUR2.
DR   PRINTS; PR01092; SULFNYLUREAR.
DR   SMART; SM00382; AAA; 2.
DR   SUPFAM; SSF52540; SSF52540; 2.
DR   SUPFAM; SSF90123; SSF90123; 2.
DR   PROSITE; PS50929; ABC_TM1F; 2.
DR   PROSITE; PS00211; ABC_TRANSPORTER_1; 2.
DR   PROSITE; PS50893; ABC_TRANSPORTER_2; 2.
PE   1: Evidence at protein level;
KW   Alternative splicing; ATP-binding; Atrial fibrillation;
KW   Cardiomyopathy; Complete proteome; Disease mutation; Glycoprotein;
KW   Membrane; Nucleotide-binding; Polymorphism; Receptor;
KW   Reference proteome; Repeat; Transmembrane; Transmembrane helix;
KW   Transport.
FT   CHAIN         1   1549       ATP-binding cassette sub-family C member
FT                                9.
FT                                /FTId=PRO_0000093402.
FT   TOPO_DOM      1     30       Extracellular. {ECO:0000255}.
FT   TRANSMEM     31     51       Helical; Name=1. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00441}.
FT   TOPO_DOM     52     72       Cytoplasmic. {ECO:0000255}.
FT   TRANSMEM     73     93       Helical; Name=2. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00441}.
FT   TOPO_DOM     94    101       Extracellular. {ECO:0000255}.
FT   TRANSMEM    102    122       Helical; Name=3. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00441}.
FT   TOPO_DOM    123    132       Cytoplasmic. {ECO:0000255}.
FT   TRANSMEM    133    153       Helical; Name=4. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00441}.
FT   TOPO_DOM    154    167       Extracellular. {ECO:0000255}.
FT   TRANSMEM    168    188       Helical; Name=5. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00441}.
FT   TOPO_DOM    189    301       Cytoplasmic. {ECO:0000255}.
FT   TRANSMEM    302    322       Helical; Name=6. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00441}.
FT   TOPO_DOM    323    350       Extracellular. {ECO:0000255}.
FT   TRANSMEM    351    371       Helical; Name=7. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00441}.
FT   TOPO_DOM    372    423       Cytoplasmic. {ECO:0000255}.
FT   TRANSMEM    424    444       Helical; Name=8. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00441}.
FT   TOPO_DOM    445    455       Extracellular. {ECO:0000255}.
FT   TRANSMEM    456    476       Helical; Name=9. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00441}.
FT   TOPO_DOM    477    531       Cytoplasmic. {ECO:0000255}.
FT   TRANSMEM    532    552       Helical; Name=10. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00441}.
FT   TOPO_DOM    553    571       Extracellular. {ECO:0000255}.
FT   TRANSMEM    572    592       Helical; Name=11. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00441}.
FT   TOPO_DOM    593    990       Cytoplasmic. {ECO:0000255}.
FT   TRANSMEM    991   1011       Helical; Name=12. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00441}.
FT   TOPO_DOM   1012   1034       Extracellular. {ECO:0000255}.
FT   TRANSMEM   1035   1055       Helical; Name=13. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00441}.
FT   TOPO_DOM   1056   1127       Cytoplasmic. {ECO:0000255}.
FT   TRANSMEM   1128   1148       Helical; Name=14. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00441}.
FT   TOPO_DOM   1149   1245       Extracellular. {ECO:0000255}.
FT   TRANSMEM   1246   1266       Helical; Name=15. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00441}.
FT   TOPO_DOM   1267   1549       Cytoplasmic. {ECO:0000255}.
FT   DOMAIN      297    597       ABC transmembrane type-1 1.
FT                                {ECO:0000255|PROSITE-ProRule:PRU00441}.
FT   DOMAIN      672    912       ABC transporter 1. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00434}.
FT   DOMAIN      994   1274       ABC transmembrane type-1 2.
FT                                {ECO:0000255|PROSITE-ProRule:PRU00441}.
FT   DOMAIN     1312   1546       ABC transporter 2. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00434}.
FT   NP_BIND     705    712       ATP 1. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00434}.
FT   NP_BIND    1346   1353       ATP 2. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00434}.
FT   CARBOHYD      9      9       N-linked (GlcNAc...) asparagine.
FT                                {ECO:0000255}.
FT   CARBOHYD    326    326       N-linked (GlcNAc...) asparagine.
FT                                {ECO:0000255}.
FT   CARBOHYD    330    330       N-linked (GlcNAc...) asparagine.
FT                                {ECO:0000255}.
FT   CARBOHYD    333    333       N-linked (GlcNAc...) asparagine.
FT                                {ECO:0000255}.
FT   CARBOHYD    334    334       N-linked (GlcNAc...) asparagine.
FT                                {ECO:0000255}.
FT   VAR_SEQ    1508   1549       SSIMDAGLVLVFSEGILVECDTVPNLLAHKNGLFSTLVMTN
FT                                K -> HTILTADLVIVMKRGNILEYDTPESLLAQENGVFAS
FT                                FVRADM (in isoform SUR2B). {ECO:0000305}.
FT                                /FTId=VSP_000058.
FT   VARIANT      60     60       H -> Y (in HTOCD; dbSNP:rs387907230).
FT                                {ECO:0000269|PubMed:22610116}.
FT                                /FTId=VAR_068485.
FT   VARIANT     207    207       D -> E (in HTOCD).
FT                                {ECO:0000269|PubMed:22610116}.
FT                                /FTId=VAR_068486.
FT   VARIANT     380    380       G -> C (in HTOCD).
FT                                {ECO:0000269|PubMed:22610116}.
FT                                /FTId=VAR_068487.
FT   VARIANT     432    432       P -> L (in HTOCD; mutant channels show
FT                                reduced ATP sensitivity; rat ABCC9
FT                                construct containing this mutation shows
FT                                gain of function).
FT                                {ECO:0000269|PubMed:22610116,
FT                                ECO:0000269|PubMed:26621776}.
FT                                /FTId=VAR_068488.
FT   VARIANT     478    478       A -> V (in HTOCD; rat ABCC9 construct
FT                                containing this mutation shows gain of
FT                                function; dbSNP:rs387907211).
FT                                {ECO:0000269|PubMed:22608503,
FT                                ECO:0000269|PubMed:26621776}.
FT                                /FTId=VAR_068489.
FT   VARIANT    1020   1020       S -> P (in HTOCD; dbSNP:rs387907229).
FT                                {ECO:0000269|PubMed:22610116}.
FT                                /FTId=VAR_068490.
FT   VARIANT    1039   1039       F -> S (in HTOCD).
FT                                {ECO:0000269|PubMed:22610116}.
FT                                /FTId=VAR_068491.
FT   VARIANT    1043   1043       C -> Y (in HTOCD; rat ABCC9 construct
FT                                containing this mutation shows gain of
FT                                function; dbSNP:rs387907210).
FT                                {ECO:0000269|PubMed:22608503,
FT                                ECO:0000269|PubMed:26621776}.
FT                                /FTId=VAR_068492.
FT   VARIANT    1054   1054       S -> Y (in HTOCD).
FT                                {ECO:0000269|PubMed:22610116}.
FT                                /FTId=VAR_068493.
FT   VARIANT    1108   1108       P -> S (in dbSNP:rs35404804).
FT                                /FTId=VAR_048143.
FT   VARIANT    1116   1116       R -> C (in HTOCD; dbSNP:rs387907228).
FT                                {ECO:0000269|PubMed:22610116}.
FT                                /FTId=VAR_068494.
FT   VARIANT    1116   1116       R -> H (in HTOCD; mutant channels show
FT                                reduced ATP sensitivity;
FT                                dbSNP:rs387907227).
FT                                {ECO:0000269|PubMed:22610116}.
FT                                /FTId=VAR_068495.
FT   VARIANT    1154   1154       R -> Q (in HTOCD; mutant channels show
FT                                reduced ATP sensitivity;
FT                                dbSNP:rs387907209).
FT                                {ECO:0000269|PubMed:22608503,
FT                                ECO:0000269|PubMed:22610116}.
FT                                /FTId=VAR_068496.
FT   VARIANT    1154   1154       R -> W (in HTOCD; dbSNP:rs387907208).
FT                                {ECO:0000269|PubMed:22608503,
FT                                ECO:0000269|PubMed:22610116}.
FT                                /FTId=VAR_068497.
FT   VARIANT    1513   1513       A -> T (in CMD1O; dbSNP:rs72559751).
FT                                {ECO:0000269|PubMed:15034580}.
FT                                /FTId=VAR_018483.
FT   VARIANT    1547   1547       T -> I (in ATFB12; compromises adenine
FT                                nucleotide-dependent induction of KATP
FT                                current; mutant ABCC9 that is co-
FT                                expressed with KCNJ11 pore generates an
FT                                aberrant channel that retains ATP-induced
FT                                inhibition of potassium current, but
FT                                shows a blunted response to ADP;
FT                                dbSNP:rs387906805).
FT                                {ECO:0000269|PubMed:17245405}.
FT                                /FTId=VAR_066210.
FT   CONFLICT    586    586       F -> S (in Ref. 1; AAC16057/AAC16058).
FT                                {ECO:0000305}.
FT   CONFLICT    589    589       S -> F (in Ref. 1; AAC16057/AAC16058).
FT                                {ECO:0000305}.
FT   CONFLICT   1503   1503       I -> M (in Ref. 1; AAC16057/AAC16058).
FT                                {ECO:0000305}.
SQ   SEQUENCE   1549 AA;  174223 MW;  55508C9343AB1218 CRC64;
     MSLSFCGNNI SSYNINDGVL QNSCFVDALN LVPHVFLLFI TFPILFIGWG SQSSKVQIHH
     NTWLHFPGHN LRWILTFALL FVHVCEIAEG IVSDSRRESR HLHLFMPAVM GFVATTTSIV
     YYHNIETSNF PKLLLALFLY WVMAFITKTI KLVKYCQSGL DISNLRFCIT GMMVILNGLL
     MAVEINVIRV RRYVFFMNPQ KVKPPEDLQD LGVRFLQPFV NLLSKATYWW MNTLIISAHK
     KPIDLKAIGK LPIAMRAVTN YVCLKDAYEE QKKKVADHPN RTPSIWLAMY RAFGRPILLS
     STFRYLADLL GFAGPLCISG IVQRVNETQN GTNNTTGISE TLSSKEFLEN AYVLAVLLFL
     ALILQRTFLQ ASYYVTIETG INLRGALLAM IYNKILRLST SNLSMGEMTL GQINNLVAIE
     TNQLMWFLFL CPNLWAMPVQ IIMGVILLYN LLGSSALVGA AVIVLLAPIQ YFIATKLAEA
     QKSTLDYSTE RLKKTNEILK GIKLLKLYAW EHIFCKSVEE TRMKELSSLK TFALYTSLSI
     FMNAAIPIAA VLATFVTHAY ASGNNLKPAE AFASLSLFHI LVTPLFLLST VVRFAVKAII
     SVQKLNEFLL SDEIGDDSWR TGESSLPFES CKKHTGVQPK TINRKQPGRY HLDSYEQSTR
     RLRPAETEDI AIKVTNGYFS WGSGLATLSN IDIRIPTGQL TMIVGQVGCG KSSLLLAILG
     EMQTLEGKVH WSNVNESEPS FEATRSRNRY SVAYAAQKPW LLNATVEENI TFGSPFNKQR
     YKAVTDACSL QPDIDLLPFG DQTEIGERGI NLSGGQRQRI CVARALYQNT NIVFLDDPFS
     ALDIHLSDHL MQEGILKFLQ DDKRTLVLVT HKLQYLTHAD WIIAMKDGSV LREGTLKDIQ
     TKDVELYEHW KTLMNRQDQE LEKDMEADQT TLERKTLRRA MYSREAKAQM EDEDEEEEEE
     EDEDDNMSTV MRLRTKMPWK TCWRYLTSGG FFLLILMIFS KLLKHSVIVA IDYWLATWTS
     EYSINNTGKA DQTYYVAGFS ILCGAGIFLC LVTSLTVEWM GLTAAKNLHH NLLNKIILGP
     IRFFDTTPLG LILNRFSADT NIIDQHIPPT LESLTRSTLL CLSAIGMISY ATPVFLVALL
     PLGVAFYFIQ KYFRVASKDL QELDDSTQLP LLCHFSETAE GLTTIRAFRH ETRFKQRMLE
     LTDTNNIAYL FLSAANRWLE VRTDYLGACI VLTASIASIS GSSNSGLVGL GLLYALTITN
     YLNWVVRNLA DLEVQMGAVK KVNSFLTMES ENYEGTMDPS QVPEHWPQEG EIKIHDLCVR
     YENNLKPVLK HVKAYIKPGQ KVGICGRTGS GKSSLSLAFF RMVDIFDGKI VIDGIDISKL
     PLHTLRSRLS IILQDPILFS GSIRFNLDPE CKCTDDRLWE ALEIAQLKNM VKSLPGGLDA
     VVTEGGENFS VGQRQLFCLA RAFVRKSSIL IMDEATASID MATENILQKV VMTAFADRTV
     VTIAHRVSSI MDAGLVLVFS EGILVECDTV PNLLAHKNGL FSTLVMTNK
//
